Facebook
X
LinkedIn
ForwardNASH: Nonalcoholic Steatohepatitis
Metabolic dysfunction-associated steatotic liver disease (MASLD) is the most common chronic liver disease worldwide. It is closely linked to obesity and type 2 diabetes, yet it often goes undiagnosed. International experts wrote the five-article Alimentary Pharmacology & Therapeutics supplement this programme is based on. It covers the global burden of MASLD, how insulin resistance and lipotoxicity drive the disease, non-invasive diagnosis and monitoring, and the role of lifestyle change and GLP-1 receptor agonists in treatment. It helps clinicians find at-risk patients earlier and manage them with evidence-based care.
Target Audience
Healthcare Professionals
Learning Objectives
- review the global perspective on NAFLD and NASH
- provide a narrative review on the performance and limitations of non-invasive tests, with a special emphasis on the impact of diabetes and obesity
- explore the most up-to-date literature on testing used for monitoring disease progression and treatment response
- review shared pathophysiologic features of common metabolic diseases and compare therapeutic strategies to reduce body weight and related complications
Activity Disclosures
Publication of this supplement is made possible by educational grant from Novo Nordisk.
Course summary
- 2.00 AMA PRA Category 1 Credit(s)™
Pegah Golabi
Pegah Golabi has nothing to disclose.
Soroor Owrangi
Soroor Owrangi has nothing to disclose
Zobair M. Younossi
Zobair M. Younossi discloses the following: Consultant to BMS, Gilead, AbbVie, Abbott, Novo Nordisk, Madrigal, Merck, Siemens and Intercept.
Shalini K. Bansal
Shalini K. Bansal has nothing to disclose.
Meena B. Bansal
Meena B. Bansal has nothing to disclose.
Wah-Kheong Chan
Wah-Kheong Chan discloses the following: Consultant or advisory board member for Roche, AbbVie, Boehringer Ingelheim and Novo Nordisk; speaker for Echosens, Viatris and Hisky Medical.
Salvatore Petta
Salvatore Petta has nothing to disclose.
Mazen Noureddin
Mazen Noureddin has nothing to disclose.
George Boon Bee Goh
George Boon Bee Goh discloses the following: Consultant or advisory board member for Boehringer Ingelheim, Gilead Sciences, Novo Nordisk and Roche Diagnostics; speaker for Abbott, Novo Nordisk and Echosens.
Vincent Wai-Sun Wong
Vincent Wai-Sun Wong discloses the following: Consultant or advisory board member for AbbVie, Boehringer Ingelheim, Echosens, Gilead Sciences, Intercept, Inventiva, Novo Nordisk, Pfizer, Sagimet Biosciences, TARGET PharmaSolutions and Visirna; speaker for Abbott, AbbVie, Gilead Sciences, Novo Nordisk and Unilab. Received a research grant from Gilead Sciences. Co-founder of Illuminatio Medical Technology Limited.
Nabil Noureddin
Nabil Noureddin has nothing to disclose.
Nedret Copur-Dahi
Nedret Copur-Dahi has nothing to disclose.
Rohit Loomba
Rohit Loomba discloses the following: Consultant to Aardvark Therapeutics, Altimmune, Alnylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Bristol-Myers Squibb, CohBar, Eli Lilly, Galmed, Gilead, Glympse bio, Hightide, Inipharma, Intercept, Inventiva, Ionis, Janssen Inc., Madrigal, Metacrine, Inc., NGM Biopharmaceuticals, Novartis, Novo Nordisk, Merck, Pfizer, Sagimet, Theratechnologies, 89bio, Terns Pharmaceuticals and Viking Therapeutics. His institutions received research grants from Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol-Myers Squibb, Eli Lilly, Galectin Therapeutics, Galmed Pharmaceuticals, Gilead, Hanmi, Intercept, Inventiva, Ionis, Janssen, Madrigal Pharmaceuticals, Merck, NGM Biopharmaceuticals, Novo Nordisk, Pfizer, Sonic Incytes and Terns Pharmaceuticals. Co-founder of LipoNexus Inc.
Anna Giannakogeorgou
Anna Giannakogeorgou has nothing to disclose.
Michael Roden
Michael Roden discloses the following: Received personal fees for consulting from AstraZeneca, Eli Lilly, Novo Nordisk and Boehringer Ingelheim. Supported for investigator-initiated trials by Boehringer Ingelheim and Novo Nordisk.
John Wiley and Sons, Inc. is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians. John Wiley and Sons, Inc. designates this enduring material for a maximum of 2.0 AMA PRA Category 1 Credit™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
For information on applicability and acceptance of continuing medical education credit for this activity, please consult your professional licensing board.
This activity is designed to be completed within 2 hours. To successfully earn credit, participants must complete the activity during the valid credit period, which is up to three years from initial publication. Additionally, a score of 70% or better is needed to pass the post test.
Available Credit
- 2.00 AMA PRA Category 1 Credit(s)™